{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:36:50Z","timestamp":1761489410924},"reference-count":35,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejcancer.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.ejca.2014.06.010","type":"journal-article","created":{"date-parts":[[2014,7,15]],"date-time":"2014-07-15T20:31:34Z","timestamp":1405456294000},"page":"2408-2416","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery"],"prefix":"10.1016","volume":"50","clinical-trial-number":[{"clinical-trial-number":"nct01253681","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01493505","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"I.","family":"Vergote","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Oaknin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-F.","family":"Baurain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Ananda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Warner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Casado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2014.06.010_b0005","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0039-6109(16)41440-4","article-title":"Intensive surgical and chemotherapeutic management of advanced ovarian cancer","volume":"58","author":"Griffiths","year":"1978","journal-title":"Surg Clin N Am"},{"issue":"10","key":"10.1016\/j.ejca.2014.06.010_b0010","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"issue":"Suppl. 3","key":"10.1016\/j.ejca.2014.06.010_b0015","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/S0959-8049(11)70152-6","article-title":"Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer","volume":"47","author":"Vergote","year":"2011","journal-title":"Eur J Cancer"},{"issue":"26","key":"10.1016\/j.ejca.2014.06.010_b0020","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.ejca.2014.06.010_b0025","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2014.06.010_b0030","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/IGC.0000000000000107","article-title":"Feasibility of interval cytoreduction following neoadjuvant chemotherapy with carboplatin, weekly paclitaxel, and bevacizumab for advanced ovarian cancer\u2014a phase 1 study","volume":"24","author":"Salani","year":"2014","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2014.06.010_b0035","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1097\/IGC.0b013e31829dc923","article-title":"Morbidity of surgery after neoadjuvant chemotherapy including bevacizumab for advanced ovarian cancer","volume":"23","author":"Chereau","year":"2013","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2014.06.010_b0040","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd2115","article-title":"Angiogenesis: an organizing principle for drug discovery?","volume":"6","author":"Folkman","year":"2007","journal-title":"Nat Rev Drug Discov"},{"issue":"20","key":"10.1016\/j.ejca.2014.06.010_b0045","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1200\/JCO.2007.11.1088","article-title":"Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition","volume":"25","author":"Martin","year":"2007","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.ejca.2014.06.010_b0050","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1200\/JCO.2002.10.088","article-title":"Vascular permeability factor\/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy","volume":"20","author":"Dvorak","year":"2002","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.ejca.2014.06.010_b0055","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1016\/j.ejca.2006.09.015","article-title":"The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review","volume":"42","author":"Eskens","year":"2006","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2014.06.010_b0060","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1470-2045(09)70362-6","article-title":"Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer","volume":"11","author":"Stone","year":"2010","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2014.06.010_b0065","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0092-8674(00)81813-9","article-title":"Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis","volume":"87","author":"Suri","year":"1996","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.ejca.2014.06.010_b0070","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0960-9822(98)70205-2","article-title":"Angiopoietin-1 induces sprouting angiogenesis in vitro","volume":"8","author":"Koblizek","year":"1998","journal-title":"Curr Biol"},{"issue":"5","key":"10.1016\/j.ejca.2014.06.010_b0075","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2353\/ajpath.2009.090391","article-title":"Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels","volume":"175","author":"Falcon","year":"2009","journal-title":"Am J Pathol"},{"issue":"5449","key":"10.1016\/j.ejca.2014.06.010_b0080","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1126\/science.286.5449.2511","article-title":"Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1","volume":"286","author":"Thurston","year":"1999","journal-title":"Science"},{"issue":"Pt 4","key":"10.1016\/j.ejca.2014.06.010_b0085","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1242\/jcs.01653","article-title":"The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism","volume":"118","author":"Scharpfenecker","year":"2005","journal-title":"J Cell Sci"},{"issue":"4","key":"10.1016\/j.ejca.2014.06.010_b0090","first-page":"1255","article-title":"The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer","volume":"61","author":"Ahmad","year":"2001","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2014.06.010_b0095","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrm2639","article-title":"Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system","volume":"10","author":"Augustin","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"10","key":"10.1016\/j.ejca.2014.06.010_b0100","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1158\/1535-7163.MCT-10-0213","article-title":"Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1\/2-neutralizing peptibody","volume":"9","author":"Coxon","year":"2010","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"10.1016\/j.ejca.2014.06.010_b0105","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ccr.2004.09.030","article-title":"Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2","volume":"6","author":"Oliner","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2014.06.010_b0110","unstructured":"Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, et al. A phase III, randomized, double-blind trial of weekly paclitaxel plus the angiopoietin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer: TRINOVA-1. European Cancer Congress 2013, September 27\u2013October 1, Amsterdam, Netherlands; 2013."},{"issue":"11","key":"10.1016\/j.ejca.2014.06.010_b0115","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1158\/1078-0432.CCR-09-3368","article-title":"Phase 1 study of AMG 386, a selective angiopoietin 1\/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors","volume":"16","author":"Mita","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.ejca.2014.06.010_b0120","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1200\/JCO.2008.19.6683","article-title":"Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors","volume":"27","author":"Herbst","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2014.06.010_b0125","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s00280-011-1787-5","article-title":"Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection","volume":"69","author":"Lu","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.ejca.2014.06.010_b0130","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1200\/JCO.2010.34.3178","article-title":"Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer","volume":"30","author":"Karlan","year":"2012","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.ejca.2014.06.010_b0135","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"issue":"Suppl. 4","key":"10.1016\/j.ejca.2014.06.010_b0140","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/annonc\/mdp117","article-title":"Newly and relapsed epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"20","author":"Aebi","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2014.06.010_b0145","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jim.2013.07.010","article-title":"Development of a biosensor-based immunogenicity assay capable of blocking soluble drug target interference","volume":"396","author":"Weeraratne","year":"2013","journal-title":"J Immunol Methods"},{"issue":"2","key":"10.1016\/j.ejca.2014.06.010_b0150","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2014.06.010_b0155","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00280-012-2000-1","article-title":"Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1\/2 antagonist, in Japanese patients with advanced solid tumors","volume":"71","author":"Doi","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.ejca.2014.06.010_b0160","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ygyno.2013.05.023","article-title":"Incidence and management of edema associated with trebananib (AMG 386)","volume":"130","author":"Monk","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2014.06.010_b0165","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.1002\/cncr.27632","article-title":"AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study","volume":"118","author":"Rini","year":"2012","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2014.06.010_b0170","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/bjc.2012.594","article-title":"A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma","volume":"108","author":"Peeters","year":"2013","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2014.06.010_b0175","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/annonc\/mds502","article-title":"Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer","volume":"24","author":"Eatock","year":"2013","journal-title":"Ann Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804914007540?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804914007540?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T08:56:16Z","timestamp":1598086576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804914007540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":35,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0959804914007540"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2014.06.010","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2014.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}